JP2010502762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502762A5 JP2010502762A5 JP2009527796A JP2009527796A JP2010502762A5 JP 2010502762 A5 JP2010502762 A5 JP 2010502762A5 JP 2009527796 A JP2009527796 A JP 2009527796A JP 2009527796 A JP2009527796 A JP 2009527796A JP 2010502762 A5 JP2010502762 A5 JP 2010502762A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- modified release
- release pharmaceutical
- inhibitor
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 9
- 239000008185 minitablet Substances 0.000 claims 6
- 238000001727 in vivo Methods 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229920006158 high molecular weight polymer Polymers 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- -1 5-chlorothien-2-yl Chemical group 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82531406P | 2006-09-12 | 2006-09-12 | |
| PCT/EP2007/059443 WO2008031782A1 (en) | 2006-09-12 | 2007-09-10 | Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010502762A JP2010502762A (ja) | 2010-01-28 |
| JP2010502762A5 true JP2010502762A5 (OSRAM) | 2010-10-28 |
Family
ID=38835794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527796A Withdrawn JP2010502762A (ja) | 2006-09-12 | 2007-09-10 | ファクターＸａ阻害剤を含有する複数のミニ錠剤を含む、医薬組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090285887A1 (OSRAM) |
| EP (1) | EP2061439A1 (OSRAM) |
| JP (1) | JP2010502762A (OSRAM) |
| KR (1) | KR20090052346A (OSRAM) |
| CN (1) | CN101516355A (OSRAM) |
| AR (1) | AR062721A1 (OSRAM) |
| AU (1) | AU2007296311A1 (OSRAM) |
| BR (1) | BRPI0716234A2 (OSRAM) |
| CA (1) | CA2662542A1 (OSRAM) |
| CL (1) | CL2007002618A1 (OSRAM) |
| EA (1) | EA200970267A1 (OSRAM) |
| IL (1) | IL197295A0 (OSRAM) |
| MX (1) | MX2009002669A (OSRAM) |
| PE (1) | PE20080661A1 (OSRAM) |
| TW (1) | TW200824723A (OSRAM) |
| WO (1) | WO2008031782A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE032540T2 (en) | 2004-06-24 | 2017-09-28 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| CA2635581C (en) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| SMT202000093T1 (it) * | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
| US20120189693A1 (en) * | 2009-06-25 | 2012-07-26 | Elite Laboratories, Inc. | Oral dosage forms |
| PL3251660T3 (pl) * | 2010-02-25 | 2020-02-28 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Formulacje apiksabanu |
| AU2015271995A1 (en) * | 2010-02-25 | 2016-01-21 | Bristol-Myers Squibb Holdings Ireland | Apixaban formulations |
| NZ607494A (en) * | 2010-08-27 | 2015-04-24 | Vertex Pharma | Pharmaceutical composition and administrations thereof |
| DK2627244T3 (en) | 2010-10-15 | 2018-10-08 | Brain Sentinel Inc | Device with EMG sensors for detecting epilepsy seizures |
| EP2554159A1 (en) * | 2011-08-04 | 2013-02-06 | ratiopharm GmbH | Dosage forms comprising apixaban and content uniformity enhancer |
| RU2692779C2 (ru) | 2012-02-27 | 2019-06-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтическая композиция и ее введения |
| KR101378973B1 (ko) * | 2012-04-13 | 2014-03-28 | 한미약품 주식회사 | 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법 |
| US20150272891A1 (en) * | 2012-05-24 | 2015-10-01 | Ratiopharm Gmbh | Dosage forms comprising apixaban and matrix former |
| CN104582692A (zh) | 2012-08-28 | 2015-04-29 | 中化帝斯曼制药有限公司荷兰公司 | 包含抗生素和β-内酰胺酶抑制剂的组合物，其中抗生素和β-内酰胺酶抑制剂中的至少一种是迷你片剂的形式 |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| CA3015607A1 (en) * | 2016-02-25 | 2017-08-31 | Mylan Inc. | A unique high-shear granulation process for improved bioavailability of rivaroxaban |
| GB201721065D0 (en) * | 2017-12-15 | 2018-01-31 | Ondosis Ab | Delivery device for drug pellets |
| KR20190130411A (ko) | 2018-05-14 | 2019-11-22 | 신일제약주식회사 | 아픽사반 약제학적 제제 및 그의 제조방법 |
| WO2025150072A1 (en) * | 2024-01-13 | 2025-07-17 | Pulse Pharmaceuticals Pvt Ltd | A stable oral pro-dispersion formulation and implementations thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1154761B1 (en) * | 1999-02-22 | 2008-02-20 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| WO2000048589A1 (en) * | 1999-02-22 | 2000-08-24 | Emisphere Holdings, Inc. | Solid oral dosage form containing heparin or a heparinoid in combination with a carrier |
| US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| GB0114004D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| MY136318A (en) * | 2002-07-25 | 2008-09-30 | Pharmacia Corp | Sustained-release tablet composition |
| KR20040076203A (ko) * | 2003-02-24 | 2004-08-31 | 주식회사 엘지생명과학 | 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법 |
| DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
-
2007
- 2007-09-10 TW TW096133641A patent/TW200824723A/zh unknown
- 2007-09-10 CL CL200702618A patent/CL2007002618A1/es unknown
- 2007-09-10 AU AU2007296311A patent/AU2007296311A1/en not_active Abandoned
- 2007-09-10 WO PCT/EP2007/059443 patent/WO2008031782A1/en not_active Ceased
- 2007-09-10 US US12/440,740 patent/US20090285887A1/en not_active Abandoned
- 2007-09-10 AR ARP070103983A patent/AR062721A1/es unknown
- 2007-09-10 EA EA200970267A patent/EA200970267A1/ru unknown
- 2007-09-10 EP EP07803361A patent/EP2061439A1/en not_active Withdrawn
- 2007-09-10 KR KR1020097005035A patent/KR20090052346A/ko not_active Withdrawn
- 2007-09-10 CN CNA2007800338980A patent/CN101516355A/zh active Pending
- 2007-09-10 BR BRPI0716234-0A patent/BRPI0716234A2/pt not_active IP Right Cessation
- 2007-09-10 PE PE2007001213A patent/PE20080661A1/es not_active Application Discontinuation
- 2007-09-10 MX MX2009002669A patent/MX2009002669A/es not_active Application Discontinuation
- 2007-09-10 CA CA002662542A patent/CA2662542A1/en not_active Abandoned
- 2007-09-10 JP JP2009527796A patent/JP2010502762A/ja not_active Withdrawn
-
2009
- 2009-02-26 IL IL197295A patent/IL197295A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010502762A5 (OSRAM) | ||
| EP2544667B1 (en) | Alcohol resistant enteric pharmaceutical compositions | |
| KR101752014B1 (ko) | 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물 | |
| US10555907B2 (en) | Controlled-release solid dosage forms of mesalamine | |
| RU2008151949A (ru) | Фармацевтические лекарственные формы и композиции фенилэфрина для абсорбции в ободочной кишке | |
| JP2009538920A5 (OSRAM) | ||
| AU2007254215A1 (en) | Methods and compositions for the treatment of viral infections | |
| CN115581696A (zh) | 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 | |
| CN104114163A (zh) | 治疗心血管疾病的方法 | |
| EP1462098B1 (en) | Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin | |
| US11813283B2 (en) | Therapeutic composition and methods | |
| WO2010014661A1 (en) | Novel method | |
| JP2004536829A5 (OSRAM) | ||
| JP2024507367A (ja) | ムスカリン受容体活性化によって改善される障害を処置するための方法 | |
| KR20190092805A (ko) | 아세틸살리실산 및 란소프라졸을 포함하는 약학적 조성물 | |
| CN102056602A (zh) | 决奈达隆用于预防心脏复律 | |
| EP4061808A1 (en) | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | |
| CN1173698C (zh) | 包含包衣的雷尼替丁、碱式柠檬酸铋和硫糖铝的对胃肠障碍具有治疗作用的可口服给药的药物制剂 | |
| JP2001511450A5 (OSRAM) | ||
| CN117136048A (zh) | 用于治疗由毒蕈碱受体激活所缓解的障碍的方法 | |
| IT201800005908A1 (it) | Compressa gastroresistente rivestita con film per il rilascio protratto di acido butirrico | |
| JP2018502168A5 (OSRAM) | ||
| AU2016344673A1 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| JP2008520607A5 (OSRAM) | ||
| JP2008143899A (ja) | 抵抗性統合失調症およびその他のｃｎｓ疾患の治療 |